NCT01116804

Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: University Hospital, Ghent · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Present imaging modalities for primary liver cancer (hepatocellular carcinoma or HCC) have several shortcomings. One important shortcoming is the time delay between successful treatment and radiological confirmation of this response. Often it takes several months for anatomical changes to occur and to be appreciated on morphological imaging such as CT or MRI (shrinkage of tumor, absence of contrast enhancement). Functional imaging by means of Fluor-18 deoxyglucose or Fluor-18 Choline (positron emitters, PET-scan) might be an early indicator of response. This "early" information might help to tailor treatment. For instance, if no response is induced, an early switch in therapy can be planned. The present study investigates whether the routine PET-tracer (Fluor-18 deoxyglucose) and the experimental PET-tracer, Fluor-18 Choline help to predict response if a patient with inoperable primary liver cancer is treated (radionuclide therapy, biologicals).

Conditions

• Primary Liver Cancer

Interventions

Type	Name	Description
PROCEDURE	MRI of the liver before start of treatment	MRI of the liver as classic work out of patients (CT-scan if MRI is contra-indicated)
PROCEDURE	MRI after treatment	MRI of the liver after 3 - 6 months of treatment (CT-scan if MRI is contra-indicated)
PROCEDURE	PET-scan before treatment start	PET-scan with 2 tracers is performed before treatment start
PROCEDURE	PET scan after treatment	PET-scan with 2 tracers is repeated 4 weeks following start of treatment

Timeline

• Start date: 2010-06-16
• Primary completion: 2020-01-20
• Completion: 2020-01-20
• First posted: 2010-05-05
• Last updated: 2022-12-15

Locations

1 site across 1 country: Belgium